Blood Market by Product (Whole Blood Collection and Processing, Source Plasma Collection, Blood Typing Products, and Blood Screening Products) and End User (Blood & Blood Component Bank, Diagnostic Laboratories, Ambulatory Surgical Centers, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
The blood market accounted for $7,201 million in 2020, and is expected to reach $10,253 million by 2027, registering a CAGR of 4.5% from 2020 to 2027.
Blood is vital for life and is required for normal functioning of the human body. Furthermore, bone marrow is responsible for the production of blood cells in the body. However, various medical conditions can lead to altered level of blood, which can be fatal for a patient. For instance, medical conditions such as chronic kidney diseases, cancer, and hemophilia B require blood transfusions for treatment. Moreover, in event of a trauma, which causes injury to a patient, blood transfusion is might be required for treatment based on the nature of the injury. Similarly, surgeries can also lead to major blood loss leading to the need for blood transfusions. Furthermore, plasma is a major content of blood and low level of plasma in the body can hamper normal functioning. Thus, patients who suffer from medical conditions such as liver diseases lead to lower plasma level requiring plasma transfusions. Thus, collection of blood is a necessary task and requires the use of reagents and blood collection systems. Moreover, the collected blood is subjected to screening, which further requires use of systems and reagents. This collected and screened blood is then circulated to various end users such as blood and blood component banks, diagnostic laboratories, ambulatory surgical centers, and hospitals.
Growth of the blood market is driven by factors such as surge in demand for blood and plasma across the globe and rise in geriatric population worldwide. In addition, increase in blood and plasma donations across the globe and favorable government regulations for blood screening are some other factors that boost the growth of the market.
Furthermore, advancements in blood transfusion and blood screening instruments is another major factor that drives growth of the blood market. However, factors such as high cost of advanced blood collection devices and lack of skilled laboratory professionals hinder the growth of the market. Conversely, developing economies offer lucrative growth opportunities for the market growth.
The blood market is segmented into product, end user, and region. On the basis of product, it is classified into whole blood collection and processing, source plasma collection, blood typing products, and blood screening products. Furthermore, all these segments are further classified into sub-segments. For instance, the whole blood collection segment is classified into whole blood collection systems and whole blood collection consumables. The source plasma collection segment is classified into source plasma collection systems and source plasma collection consumables. In addition, the blood typing products are further bifurcated into blood typing systems, blood typing reagents. The blood screening products are divided into blood screening systems, and blood screening reagents.
On the basis of end user, the market is divided into blood and blood component bank, diagnostic laboratories, ambulatory surgical centers, hospitals, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Bio-Rad Laboratories, Inc., CSL Limited (CSL Behring), F. Hoffmann-La Roche Ltd., Grifols International SA, Haemonetics Corporation, Merck & Co., Inc., Novo Nordisk A/S, Ortho Clinical Diagnostics, and Terumo Corporation (Terumo BCT, Inc.) are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
Blood is vital for life and is required for normal functioning of the human body. Furthermore, bone marrow is responsible for the production of blood cells in the body. However, various medical conditions can lead to altered level of blood, which can be fatal for a patient. For instance, medical conditions such as chronic kidney diseases, cancer, and hemophilia B require blood transfusions for treatment. Moreover, in event of a trauma, which causes injury to a patient, blood transfusion is might be required for treatment based on the nature of the injury. Similarly, surgeries can also lead to major blood loss leading to the need for blood transfusions. Furthermore, plasma is a major content of blood and low level of plasma in the body can hamper normal functioning. Thus, patients who suffer from medical conditions such as liver diseases lead to lower plasma level requiring plasma transfusions. Thus, collection of blood is a necessary task and requires the use of reagents and blood collection systems. Moreover, the collected blood is subjected to screening, which further requires use of systems and reagents. This collected and screened blood is then circulated to various end users such as blood and blood component banks, diagnostic laboratories, ambulatory surgical centers, and hospitals.
Growth of the blood market is driven by factors such as surge in demand for blood and plasma across the globe and rise in geriatric population worldwide. In addition, increase in blood and plasma donations across the globe and favorable government regulations for blood screening are some other factors that boost the growth of the market.
Furthermore, advancements in blood transfusion and blood screening instruments is another major factor that drives growth of the blood market. However, factors such as high cost of advanced blood collection devices and lack of skilled laboratory professionals hinder the growth of the market. Conversely, developing economies offer lucrative growth opportunities for the market growth.
The blood market is segmented into product, end user, and region. On the basis of product, it is classified into whole blood collection and processing, source plasma collection, blood typing products, and blood screening products. Furthermore, all these segments are further classified into sub-segments. For instance, the whole blood collection segment is classified into whole blood collection systems and whole blood collection consumables. The source plasma collection segment is classified into source plasma collection systems and source plasma collection consumables. In addition, the blood typing products are further bifurcated into blood typing systems, blood typing reagents. The blood screening products are divided into blood screening systems, and blood screening reagents.
On the basis of end user, the market is divided into blood and blood component bank, diagnostic laboratories, ambulatory surgical centers, hospitals, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Bio-Rad Laboratories, Inc., CSL Limited (CSL Behring), F. Hoffmann-La Roche Ltd., Grifols International SA, Haemonetics Corporation, Merck & Co., Inc., Novo Nordisk A/S, Ortho Clinical Diagnostics, and Terumo Corporation (Terumo BCT, Inc.) are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global blood market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
- By Product
- Whole Blood Collection and Processing
- Whole Blood Collection Systems
- Whole Blood Collection Consumables
- Source Plasma Collection
- Source Plasma Collection Systems
- Source Plasma Collection Consumables
- Blood Typing Products
- Blood Typing Systems
- Blood Typing Reagents
- Blood Screening Products
- Blood Screening Systems
- Blood Screening Reagents
- By End User
- Blood & Blood Component Bank
- Diagnostic Laboratories
- Ambulatory Surgical Centers
- Blood And Blood Component Bank
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- List of key players profiled in the report:
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- CSL Limited (CSL Behring).
- F. Hoffmann-La Roche Ltd.
- Grifols International SA
- Haemonetics Corporation
- Merck & Co., Inc.
- Novo Nordisk A/S
- Ortho Clinical Diagnostics
- Terumo Corporation (Terumo BCT, Inc.)
- Fresenius Kabi
- Qiagen N.V.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top player positioning
3.2.1.Top investment pockets
3.3.Key forces shaping blood industry/Market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in demand for blood and other blood related products across the globe
3.4.1.2.Rise in geriatric population across the globe
3.4.1.3.Surge in blood donations and plasma donations across the globe
3.4.1.4.Favorable government regulations for blood screening
3.4.1.5.Advancements in blood transfusion and blood screening instruments
3.4.2.Restraints
3.4.2.1.High cost of advanced blood collection devices
3.4.2.2.Lack of skilled laboratory professionals
3.4.3.Opportunities
3.4.3.1.Developing economies offer lucrative growth opportunities
3.4.4.Impact Analysis
3.5.Blood Therapeutics
3.5.1.Key market trends, growth factors, and opportunities
3.5.2.Market size and forecast, by product
3.5.2.1.Intravenous Immunoglobulin
3.5.2.1.1.Market size and forecast
3.5.2.2.Factor IX
3.5.2.2.1.Market size and forecast
3.5.2.3.Factor VIII
3.5.2.3.1.Market size and forecast
3.5.2.4.Albumin
3.5.2.4.1.Market size and forecast
3.5.2.5.Hyperimmune
3.5.2.5.1.Market size and forecast
3.5.2.6.Others
3.5.2.6.1.Market size and forecast
3.5.3.Market size and forecast, by region
CHAPTER 4:BLOOD MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Whole blood collection and processing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Whole Blood Collection and Processing Systems
4.2.2.1.1.Market size and forecast
4.2.2.1.2.Market size and forecast, by region
4.2.2.2.Whole Blood Collection and Processing Consumables
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by region
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Source plasma collection
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Source Plasma Collection Systems
4.3.2.1.1.Market size and forecast
4.3.2.1.2.Market size and forecast, by region
4.3.2.2.Source Plasma Collection Consumables
4.3.2.2.1.Market size and forecast
4.3.2.2.2.Market size and forecast, by region
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Blood typing products
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Blood Typing Systems
4.4.2.1.1.Market size and forecast
4.4.2.1.2.Market size and forecast, by region
4.4.2.2.Blood Typing Reagents
4.4.2.2.1.Market size and forecast
4.4.2.2.2.Market size and forecast, by region
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Blood screening products
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Blood Screening Systems
4.5.2.1.1.Market size and forecast
4.5.2.1.2.Market size and forecast, by region
4.5.2.2.Blood Screening Reagents
4.5.2.2.1.Market size and forecast
4.5.2.2.2.Market size and forecast, by region
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
CHAPTER 5:BLOOD MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Blood and blood component bank
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Diagnostic laboratories
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Ambulatory surgical centers
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Hospitals
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:BLOOD MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market analysis, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. blood market size and forecast, by product
6.2.2.1.2.U.S. blood market size and forecast, by end user
6.2.2.2.Canada
6.2.2.2.1.Canada blood market size and forecast, by product
6.2.2.2.2.Canada blood market size and forecast, by end user
6.2.2.3.Mexico
6.2.2.3.1.Mexico blood market size and forecast, by product
6.2.2.3.2.Mexico blood market size and forecast, by end use
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by end user
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market analysis, by country
6.3.2.1.Germany
6.3.2.1.1.Germany blood market size and forecast, by product
6.3.2.1.2.Germany blood market size and forecast, by end user
6.3.2.2.France
6.3.2.2.1.France blood market size and forecast, by product
6.3.2.2.2.France blood market size and forecast, by end user
6.3.2.3.UK
6.3.2.3.1.UK blood market size and forecast, by product
6.3.2.3.2.UK blood market size and forecast, by end user
6.3.2.4.Italy
6.3.2.4.1.Italy blood market size and forecast, by product
6.3.2.4.2.Italy blood market size and forecast, by end user
6.3.2.5.Spain
6.3.2.5.1.Spain blood market size and forecast, by product
6.3.2.5.2.Spain blood market size and forecast, by end user
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe blood market size and forecast, by product
6.3.2.6.2.Rest of Europe blood market size and forecast, by end user
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by end user
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market analysis, by country
6.4.2.1.Japan
6.4.2.1.1.Japan blood market size and forecast, by product
6.4.2.1.2.Japan blood market size and forecast, by end user
6.4.2.2.China
6.4.2.2.1.China blood market size and forecast, by product
6.4.2.2.2.China blood market size and forecast, by end user
6.4.2.3.Australia
6.4.2.3.1.Australia blood market size and forecast, by product
6.4.2.3.2.Australia blood market size and forecast, by end user
6.4.2.4.India
6.4.2.4.1.India blood market size and forecast, by product
6.4.2.4.2.India blood market size and forecast, by end user
6.4.2.5.South Korea
6.4.2.5.1.South Korea blood market size and forecast, by product
6.4.2.5.2.South Korea blood market size and forecast, by end user
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific blood market size and forecast, by product
6.4.2.6.2.Rest of Asia-Pacific blood market size and forecast, by end user
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by end user
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market analysis, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil blood market size and forecast, by product
6.5.2.1.2.Brazil blood market size and forecast, by end user
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia blood market size and forecast, by product
6.5.2.2.2.Saudi Arabia blood market size and forecast, by end user
6.5.2.3.South Africa
6.5.2.3.1.South Africa blood market size and forecast, by product
6.5.2.3.2.South Africa blood market size and forecast, by end user
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA blood market size and forecast, by product
6.5.2.4.2.Rest of LAMEA blood market size and forecast, by end user
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.1.2.1. Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BIO-RAD LABORATORIES, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.CSL LIMITED (CSL BEHRING)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.F. HOFFMANN-LA ROCHE LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS INTERNATIONAL SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.HAEMONETICS CORPORATION
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MERCK & CO., INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.NOVO NORDISK A/S
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.ORTHO CLINICAL DIAGNOSTICS
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Key strategic moves and developments
7.10.TERUMO CORPORATION (TERUMO BCT, INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Top player positioning
3.2.1.Top investment pockets
3.3.Key forces shaping blood industry/Market
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in demand for blood and other blood related products across the globe
3.4.1.2.Rise in geriatric population across the globe
3.4.1.3.Surge in blood donations and plasma donations across the globe
3.4.1.4.Favorable government regulations for blood screening
3.4.1.5.Advancements in blood transfusion and blood screening instruments
3.4.2.Restraints
3.4.2.1.High cost of advanced blood collection devices
3.4.2.2.Lack of skilled laboratory professionals
3.4.3.Opportunities
3.4.3.1.Developing economies offer lucrative growth opportunities
3.4.4.Impact Analysis
3.5.Blood Therapeutics
3.5.1.Key market trends, growth factors, and opportunities
3.5.2.Market size and forecast, by product
3.5.2.1.Intravenous Immunoglobulin
3.5.2.1.1.Market size and forecast
3.5.2.2.Factor IX
3.5.2.2.1.Market size and forecast
3.5.2.3.Factor VIII
3.5.2.3.1.Market size and forecast
3.5.2.4.Albumin
3.5.2.4.1.Market size and forecast
3.5.2.5.Hyperimmune
3.5.2.5.1.Market size and forecast
3.5.2.6.Others
3.5.2.6.1.Market size and forecast
3.5.3.Market size and forecast, by region
CHAPTER 4:BLOOD MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Whole blood collection and processing
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Whole Blood Collection and Processing Systems
4.2.2.1.1.Market size and forecast
4.2.2.1.2.Market size and forecast, by region
4.2.2.2.Whole Blood Collection and Processing Consumables
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Market size and forecast, by region
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Source plasma collection
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Source Plasma Collection Systems
4.3.2.1.1.Market size and forecast
4.3.2.1.2.Market size and forecast, by region
4.3.2.2.Source Plasma Collection Consumables
4.3.2.2.1.Market size and forecast
4.3.2.2.2.Market size and forecast, by region
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Blood typing products
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Blood Typing Systems
4.4.2.1.1.Market size and forecast
4.4.2.1.2.Market size and forecast, by region
4.4.2.2.Blood Typing Reagents
4.4.2.2.1.Market size and forecast
4.4.2.2.2.Market size and forecast, by region
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Blood screening products
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Blood Screening Systems
4.5.2.1.1.Market size and forecast
4.5.2.1.2.Market size and forecast, by region
4.5.2.2.Blood Screening Reagents
4.5.2.2.1.Market size and forecast
4.5.2.2.2.Market size and forecast, by region
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
CHAPTER 5:BLOOD MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Blood and blood component bank
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Diagnostic laboratories
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Ambulatory surgical centers
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Hospitals
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:BLOOD MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market analysis, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. blood market size and forecast, by product
6.2.2.1.2.U.S. blood market size and forecast, by end user
6.2.2.2.Canada
6.2.2.2.1.Canada blood market size and forecast, by product
6.2.2.2.2.Canada blood market size and forecast, by end user
6.2.2.3.Mexico
6.2.2.3.1.Mexico blood market size and forecast, by product
6.2.2.3.2.Mexico blood market size and forecast, by end use
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by end user
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market analysis, by country
6.3.2.1.Germany
6.3.2.1.1.Germany blood market size and forecast, by product
6.3.2.1.2.Germany blood market size and forecast, by end user
6.3.2.2.France
6.3.2.2.1.France blood market size and forecast, by product
6.3.2.2.2.France blood market size and forecast, by end user
6.3.2.3.UK
6.3.2.3.1.UK blood market size and forecast, by product
6.3.2.3.2.UK blood market size and forecast, by end user
6.3.2.4.Italy
6.3.2.4.1.Italy blood market size and forecast, by product
6.3.2.4.2.Italy blood market size and forecast, by end user
6.3.2.5.Spain
6.3.2.5.1.Spain blood market size and forecast, by product
6.3.2.5.2.Spain blood market size and forecast, by end user
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe blood market size and forecast, by product
6.3.2.6.2.Rest of Europe blood market size and forecast, by end user
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by end user
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market analysis, by country
6.4.2.1.Japan
6.4.2.1.1.Japan blood market size and forecast, by product
6.4.2.1.2.Japan blood market size and forecast, by end user
6.4.2.2.China
6.4.2.2.1.China blood market size and forecast, by product
6.4.2.2.2.China blood market size and forecast, by end user
6.4.2.3.Australia
6.4.2.3.1.Australia blood market size and forecast, by product
6.4.2.3.2.Australia blood market size and forecast, by end user
6.4.2.4.India
6.4.2.4.1.India blood market size and forecast, by product
6.4.2.4.2.India blood market size and forecast, by end user
6.4.2.5.South Korea
6.4.2.5.1.South Korea blood market size and forecast, by product
6.4.2.5.2.South Korea blood market size and forecast, by end user
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific blood market size and forecast, by product
6.4.2.6.2.Rest of Asia-Pacific blood market size and forecast, by end user
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by end user
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market analysis, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil blood market size and forecast, by product
6.5.2.1.2.Brazil blood market size and forecast, by end user
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia blood market size and forecast, by product
6.5.2.2.2.Saudi Arabia blood market size and forecast, by end user
6.5.2.3.South Africa
6.5.2.3.1.South Africa blood market size and forecast, by product
6.5.2.3.2.South Africa blood market size and forecast, by end user
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA blood market size and forecast, by product
6.5.2.4.2.Rest of LAMEA blood market size and forecast, by end user
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.1.2.1. Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BIO-RAD LABORATORIES, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.CSL LIMITED (CSL BEHRING)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.F. HOFFMANN-LA ROCHE LTD.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.GRIFOLS INTERNATIONAL SA
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.HAEMONETICS CORPORATION
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MERCK & CO., INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.NOVO NORDISK A/S
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.ORTHO CLINICAL DIAGNOSTICS
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Key strategic moves and developments
7.10.TERUMO CORPORATION (TERUMO BCT, INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY TYPE 2019–2027 ($MILLION)
TABLE 02.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY REGION 2019–2027 ($MILLION)
TABLE 03.GLOBAL BLOOD MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY TYPE 2019–2027 ($MILLION)
TABLE 05.WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 06.WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 07.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY REGION, 2019–2027 ($MILLION)
TABLE 08.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY TYPE 2019–2027 ($MILLION)
TABLE 09.SOURCE PLASMA COLLECTION SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 10.PLASMA COLLECTION CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 11.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 13.BLOOD TYPING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 14.BLOOD TYPING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 15.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 16.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 17.BLOOD SCREENING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 18.BLOOD SCREENING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 19.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.GLOBAL BLOOD MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 21.BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY REGION 2019–2027($MILLION)
TABLE 22.BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION 2019–2027($MILLION)
TABLE 23.BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION 2019–2027($MILLION)
TABLE 24.BLOOD MARKET FOR HOSPITALS, BY REGION 2019–2027($MILLION)
TABLE 25.BLOOD MARKET FOR OTHERS , BY REGION 2019–2027($MILLION)
TABLE 26.BLOOD MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 27.SCREENING OF DONATED BLOOD IN U.S.
TABLE 28.NORTH AMERICA BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 29.U.S. BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 30.U.S. BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 31.CANADA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 32.CANADA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 33.MEXICO BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 34.MEXICO BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 35.NORTH AMERICA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 36.NORTH AMERICA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 37.EUROPE BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 38.GERMANY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 39.GERMANY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 40.FRANCE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 41.FRANCE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 42.UK BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 43.UK BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 44.ITALY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 45.ITALY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 46.SPAIN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 47.SPAIN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 48.REST OF EUROPE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 49.REST OF EUROPE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 50.EUROPE BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 51.EUROPE BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 52.ASIA-PACIFIC BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 53.JAPAN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 54.JAPAN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 55.CHINA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 56.CHINA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 57.AUSTRALIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 58.AUSTRALIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 59.INDIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 60.INDIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 61.SOUTH KOREA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 62.SOUTH KOREA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 66.ASIA-PACIFIC BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 67.MIDDLE EAST BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 68.BRAZIL BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 69.BRAZIL BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 70.SAUDI ARABIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 71.SAUDI ARABIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 72.SOUTH AFRICA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 73.SOUTH AFRICA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 74.REST OF LAMEA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 75.REST OF LAMEA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 76.LAMEA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 77.LAMEA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 78.ABBOTT: COMPANY SNAPSHOT
TABLE 79.ABBOTT: OERATING SEGMENT
TABLE 80.ABBOTT: PRODUCT PORTFOLIO
TABLE 81.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82.BIO-RAD: COMPANY SNAPSHOT
TABLE 83.BIO-RAD: OERATING SEGMENT
TABLE 84.BIO-RAD: PRODUCT PORTFOLIO
TABLE 85.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 86.CSL: COMPANY SNAPSHOT
TABLE 87.CSL: OERATING SEGMENT
TABLE 88.CSL: PRODUCT PORTFOLIO
TABLE 89.ROCHE: COMPANY SNAPSHOT
TABLE 90.ROCHE: OERATING SEGMENT
TABLE 91.ROCHE: PRODUCT PORTFOLIO
TABLE 92.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.GRIFOLS: COMPANY SNAPSHOT
TABLE 94.GRIFOLS: OERATING SEGMENT
TABLE 95.GRIFOLS: PRODUCT PORTFOLIO
TABLE 96.GRIFOLS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.HAEMONETICS: COMPANY SNAPSHOT
TABLE 98.HAEMONETICS: OPERATING SEGMENTS
TABLE 99.HAEMONETICS: PRODUCT PORTFOLIO
TABLE 100.HAEMONETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.MERCK: COMPANY SNAPSHOT
TABLE 102.MERCK: OPERATING SEGMENTS
TABLE 103.MERCK PRODUCT PORTFOLIO
TABLE 104.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 105.NOVO NORDISK: OERATING SEGMENT
TABLE 106.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 107.NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108.ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 109.ORTHO CLINICAL DIAGNOSTICS.: PRODUCT PORTFOLIO
TABLE 110.ORTHO CLINICAL DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111.TERUMO: COMPANY SNAPSHOT
TABLE 112.TERUMO: OERATING SEGMENT
TABLE 113.TERUMO: PRODUCT PORTFOLIO
TABLE 01.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY TYPE 2019–2027 ($MILLION)
TABLE 02.BLOOD MARKET FOR BLOOD THERAPEUTICS, BY REGION 2019–2027 ($MILLION)
TABLE 03.GLOBAL BLOOD MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY TYPE 2019–2027 ($MILLION)
TABLE 05.WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 06.WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 07.BLOOD MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING, BY REGION, 2019–2027 ($MILLION)
TABLE 08.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY TYPE 2019–2027 ($MILLION)
TABLE 09.SOURCE PLASMA COLLECTION SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 10.PLASMA COLLECTION CONSUMABLES MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 11.BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 13.BLOOD TYPING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 14.BLOOD TYPING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 15.BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 16.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY TYPE 2019–2027 ($MILLION)
TABLE 17.BLOOD SCREENING SYSTEMS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 18.BLOOD SCREENING REAGENTS MARKET, BY REGION 2019–2027 ($MILLION)
TABLE 19.BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.GLOBAL BLOOD MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 21.BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY REGION 2019–2027($MILLION)
TABLE 22.BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION 2019–2027($MILLION)
TABLE 23.BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION 2019–2027($MILLION)
TABLE 24.BLOOD MARKET FOR HOSPITALS, BY REGION 2019–2027($MILLION)
TABLE 25.BLOOD MARKET FOR OTHERS , BY REGION 2019–2027($MILLION)
TABLE 26.BLOOD MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 27.SCREENING OF DONATED BLOOD IN U.S.
TABLE 28.NORTH AMERICA BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 29.U.S. BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 30.U.S. BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 31.CANADA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 32.CANADA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 33.MEXICO BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 34.MEXICO BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 35.NORTH AMERICA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 36.NORTH AMERICA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 37.EUROPE BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 38.GERMANY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 39.GERMANY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 40.FRANCE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 41.FRANCE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 42.UK BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 43.UK BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 44.ITALY BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 45.ITALY BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 46.SPAIN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 47.SPAIN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 48.REST OF EUROPE BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 49.REST OF EUROPE BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 50.EUROPE BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 51.EUROPE BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 52.ASIA-PACIFIC BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 53.JAPAN BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 54.JAPAN BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 55.CHINA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 56.CHINA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 57.AUSTRALIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 58.AUSTRALIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 59.INDIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 60.INDIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 61.SOUTH KOREA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 62.SOUTH KOREA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 63.REST OF ASIA-PACIFIC BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 66.ASIA-PACIFIC BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 67.MIDDLE EAST BLOOD MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 68.BRAZIL BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 69.BRAZIL BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 70.SAUDI ARABIA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 71.SAUDI ARABIA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 72.SOUTH AFRICA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 73.SOUTH AFRICA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 74.REST OF LAMEA BLOOD MARKET, BY PRODUCT TYPE, 2020–2027 ($MILLION)
TABLE 75.REST OF LAMEA BLOOD MARKET, BY END USER, 2020–2027 ($MILLION)
TABLE 76.LAMEA BLOOD MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 77.LAMEA BLOOD MARKET REVENUE, BY END USER, 2020–2027($MILLION)
TABLE 78.ABBOTT: COMPANY SNAPSHOT
TABLE 79.ABBOTT: OERATING SEGMENT
TABLE 80.ABBOTT: PRODUCT PORTFOLIO
TABLE 81.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82.BIO-RAD: COMPANY SNAPSHOT
TABLE 83.BIO-RAD: OERATING SEGMENT
TABLE 84.BIO-RAD: PRODUCT PORTFOLIO
TABLE 85.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 86.CSL: COMPANY SNAPSHOT
TABLE 87.CSL: OERATING SEGMENT
TABLE 88.CSL: PRODUCT PORTFOLIO
TABLE 89.ROCHE: COMPANY SNAPSHOT
TABLE 90.ROCHE: OERATING SEGMENT
TABLE 91.ROCHE: PRODUCT PORTFOLIO
TABLE 92.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 93.GRIFOLS: COMPANY SNAPSHOT
TABLE 94.GRIFOLS: OERATING SEGMENT
TABLE 95.GRIFOLS: PRODUCT PORTFOLIO
TABLE 96.GRIFOLS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.HAEMONETICS: COMPANY SNAPSHOT
TABLE 98.HAEMONETICS: OPERATING SEGMENTS
TABLE 99.HAEMONETICS: PRODUCT PORTFOLIO
TABLE 100.HAEMONETICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.MERCK: COMPANY SNAPSHOT
TABLE 102.MERCK: OPERATING SEGMENTS
TABLE 103.MERCK PRODUCT PORTFOLIO
TABLE 104.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 105.NOVO NORDISK: OERATING SEGMENT
TABLE 106.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 107.NOVO NORDISK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108.ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 109.ORTHO CLINICAL DIAGNOSTICS.: PRODUCT PORTFOLIO
TABLE 110.ORTHO CLINICAL DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111.TERUMO: COMPANY SNAPSHOT
TABLE 112.TERUMO: OERATING SEGMENT
TABLE 113.TERUMO: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL BLOOD MARKET SEGMENTATION
FIGURE 02.TOP PLAYER POSITIONING, 2018
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
FIGURE 06.LOW THREAT OF SUBSTITUTES
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.MODERATE THREAT OF NEW ENTRANT
FIGURE 09.GERIATRIC POPULATION (%), 2017-2018
FIGURE 10.IMPACT ANALYSIS, BLOOD MARKET
FIGURE 11.BLOOD THERAPEUTICS MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, 2019–2027 ($MILLION)
FIGURE 12.BLOOD THERAPEUTICS MARKET FOR FACTOR IX, 2019–2027 ($MILLION)
FIGURE 13.BLOOD THERAPEUTICS MARKET FOR FACTOR VIII, 2019–2027 ($MILLION)
FIGURE 14.BLOOD THERAPEUTICS MARKET FOR ALBUMIN, 2019–2027 ($MILLION)
FIGURE 15.BLOOD THERAPEUTICS MARKET FOR HYPERIMMUNE, 2019–2027 ($MILLION)
FIGURE 16.BLOOD THERAPEUTICS MARKET FOR OTEHRS, 2019–2027 ($MILLION)
FIGURE 17.WHOLE BLOOD COLLECTION AND PROCESSING MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 18.WHOLE BLOOD COLLECTION AND PROCESSING MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR WHOLE BLOOD COLLECTION, BY COUNTRY, 2019 & 2027(%)
FIGURE 20.COMPOSITION OF PLASMA
FIGURE 21.PLASMA COLLECTION MARKET FOR SOURCE PLASMA COLLECTION SYSTEMS, 2019–2027 ($MILLION)
FIGURE 22.PLASMA COLLECTION MARKET FOR SOURCE PLASMA COLLECTION CONSUMABLES, 2019–2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY COUNTRY, 2019 & 2027(%)
FIGURE 24.BLOOD TYPING MARKET FOR BLOOD TYPING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 25.BLOOD TYPING MARKET FOR BLOOD TYPING REAGENTS, 2019–2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY COUNTRY, 2019 & 2027(%)
FIGURE 27.BLOOD SCREENING MARKET FOR BLOOD TYPING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 28.BLOOD SCREENING MARKET FOR BLOOD SCREENING REAGENTS, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY COUNTRY, 2019 & 2027(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 34.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 35.U.S. BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 36.CANADA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 37.MEXICO BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 38.GERMANY BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 39.FRANCE BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 40.UK BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 41.ITALY BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 42.SPAIN BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 43.REST OF EUROPE BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 44.JAPAN BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 45.CHINA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 46.AUSTRALIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 47.INDIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 48.SOUTH KOREA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 49.REST OF ASIA-PACIFIC BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 50.BRAZIL BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 51.SAUDI ARABIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 52.SOUTH AFRICA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 53.REST OF LAMEA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 54.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 56.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 57.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 59.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.CSL: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.CSL: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 62.CSL: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 63.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 65.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.GRIFOLS: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.GRIFOLS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 68.GRIFOLS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 69.HAEMONETICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 70.HAEMONETICS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 71.HAEMONETICS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 72.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.MERCK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 74.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 75.NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 76.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 77.NOVO NORDISK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 78.TERUMO: NET SALES, 2017–2019 ($MILLION)
FIGURE 79.TERUMO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 80.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.GLOBAL BLOOD MARKET SEGMENTATION
FIGURE 02.TOP PLAYER POSITIONING, 2018
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05.MODERATE BARGAINING POWER OF BUYERS
FIGURE 06.LOW THREAT OF SUBSTITUTES
FIGURE 07.MODERATE INTENSITY OF RIVALRY
FIGURE 08.MODERATE THREAT OF NEW ENTRANT
FIGURE 09.GERIATRIC POPULATION (%), 2017-2018
FIGURE 10.IMPACT ANALYSIS, BLOOD MARKET
FIGURE 11.BLOOD THERAPEUTICS MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, 2019–2027 ($MILLION)
FIGURE 12.BLOOD THERAPEUTICS MARKET FOR FACTOR IX, 2019–2027 ($MILLION)
FIGURE 13.BLOOD THERAPEUTICS MARKET FOR FACTOR VIII, 2019–2027 ($MILLION)
FIGURE 14.BLOOD THERAPEUTICS MARKET FOR ALBUMIN, 2019–2027 ($MILLION)
FIGURE 15.BLOOD THERAPEUTICS MARKET FOR HYPERIMMUNE, 2019–2027 ($MILLION)
FIGURE 16.BLOOD THERAPEUTICS MARKET FOR OTEHRS, 2019–2027 ($MILLION)
FIGURE 17.WHOLE BLOOD COLLECTION AND PROCESSING MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 18.WHOLE BLOOD COLLECTION AND PROCESSING MARKET FOR WHOLE BLOOD COLLECTION AND PROCESSING CONSUMABLES, 2019–2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR WHOLE BLOOD COLLECTION, BY COUNTRY, 2019 & 2027(%)
FIGURE 20.COMPOSITION OF PLASMA
FIGURE 21.PLASMA COLLECTION MARKET FOR SOURCE PLASMA COLLECTION SYSTEMS, 2019–2027 ($MILLION)
FIGURE 22.PLASMA COLLECTION MARKET FOR SOURCE PLASMA COLLECTION CONSUMABLES, 2019–2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR SOURCE PLASMA COLLECTION, BY COUNTRY, 2019 & 2027(%)
FIGURE 24.BLOOD TYPING MARKET FOR BLOOD TYPING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 25.BLOOD TYPING MARKET FOR BLOOD TYPING REAGENTS, 2019–2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR BLOOD TYPING PRODUCTS, BY COUNTRY, 2019 & 2027(%)
FIGURE 27.BLOOD SCREENING MARKET FOR BLOOD TYPING SYSTEMS, 2019–2027 ($MILLION)
FIGURE 28.BLOOD SCREENING MARKET FOR BLOOD SCREENING REAGENTS, 2019–2027 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF BLOOD MARKET FOR BLOOD SCREENING PRODUCTS, BY COUNTRY, 2019 & 2027(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR BLOOD AND BLOOD COMPONENT BANK, BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 33.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 34.COMPARATIVE SHARE ANALYSIS OF BLOOD MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 35.U.S. BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 36.CANADA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 37.MEXICO BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 38.GERMANY BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 39.FRANCE BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 40.UK BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 41.ITALY BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 42.SPAIN BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 43.REST OF EUROPE BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 44.JAPAN BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 45.CHINA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 46.AUSTRALIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 47.INDIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 48.SOUTH KOREA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 49.REST OF ASIA-PACIFIC BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 50.BRAZIL BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 51.SAUDI ARABIA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 52.SOUTH AFRICA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 53.REST OF LAMEA BLOOD MARKET, 2020–2027 ($MILLION)
FIGURE 54.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 56.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 57.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.BIO-RAD: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 59.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.CSL: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.CSL: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 62.CSL: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 63.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 65.ROCHE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.GRIFOLS: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.GRIFOLS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 68.GRIFOLS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 69.HAEMONETICS: NET SALES, 2017–2019 ($MILLION)
FIGURE 70.HAEMONETICS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 71.HAEMONETICS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 72.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 73.MERCK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 74.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 75.NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 76.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 77.NOVO NORDISK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 78.TERUMO: NET SALES, 2017–2019 ($MILLION)
FIGURE 79.TERUMO: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 80.TERUMO: REVENUE SHARE, BY REGION, 2019 (%)
